Recent data suggest that bivalirudin, a reversible direct thrombin inhibitor, may be
noninferior to heparins (unfractionated heparin/low molecular weight heparin) in providing …

Objective: This study evaluates outcomes with bivalirudin vs heparin in various patient
subgroups and the overall population during percutaneous coronary interventions (PCI) …

Aims The efficacy and safety of bivalirudin in patients undergoing percutaneous coronary
intervention (PCI) for treatment of acute coronary syndromes (ACS) remains controversial …

Background Bivalirudin is an alternative accepted therapy to unfractionated heparin for
patients with myocardial infarction (MI) undergoing percutaneous coronary intervention …

Background: This meta-analysis is to evaluate the efficacy and safety of bivalirudin in
patients with ST-elevation myocardial infarction (STEMI). Methods: PubMed, Cochrane …

Recent clinical trials have shown that while bivalirudin exhibits similar efficacy with heparin,
it offers several advantages over heparin, such as a better safety profile. We aimed to …

Aims: Current recommendations on the use of bivalirudin in patients treated with
percutaneous coronary intervention (PCI) are mostly based on trials comparing bivalirudin …

Introduction and objectives Contrasting data have been reported on bivalirudin as an
anticoagulation strategy during percutaneous coronary interventions, offering theoretical …

Introduction: Bivalirudin and heparin are the two most commonly used anticoagulants used
during Percutaneous Coronary Intervention (PCI). The results of Randomized Controlled …

A series of trials have shown that bivalirudin, a direct thrombin inhibitor that does not require
the cofactor antithrombin III to be effective, is a reasonable alternative to unfractionated …